TIRZEPATIDE - Generic Drug Details

What are the generic drug sources for tirzepatide and what is the scope of freedom to operate?

Tirzepatide is the generic ingredient in six branded drugs marketed by Eli Lilly And Co and is included in two NDAs. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Tirzepatide has two hundred and one patent family members in forty-six countries.

One supplier is listed for this compound.

Summary for TIRZEPATIDE

International Patents:	201
US Patents:	8
Tradenames:	6
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	5
Clinical Trials:	166
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TIRZEPATIDE
What excipients (inactive ingredients) are in TIRZEPATIDE?	TIRZEPATIDE excipients list
DailyMed Link:	TIRZEPATIDE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TIRZEPATIDE

Constraining patent/regulatory exclusivity:

9,474,780

Dosage:

SOLUTION;SUBCUTANEOUS

Constraining patent/regulatory exclusivity:

9,474,780

Dosage:

SOLUTION;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TIRZEPATIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
First Affiliated Hospital of Wenzhou Medical University	PHASE2
University of Virginia	PHASE3
University Medical Centre Ljubljana	PHASE4

See all TIRZEPATIDE clinical trials

Pharmacology for TIRZEPATIDE

Drug Class	GLP-1 Receptor Agonist Glucose-dependent Insulinotropic Polypeptide Receptor Agonist
Mechanism of Action	G-Protein-linked Receptor Interactions Glucagon-like Peptide-1 (GLP-1) Agonists

Anatomical Therapeutic Chemical (ATC) Classes for TIRZEPATIDE

A10BX	Other blood glucose lowering drugs, excl. insulins
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10	DRUGS USED IN DIABETES
A	Alimentary tract and metabolism

US Patents and Regulatory Information for TIRZEPATIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eli Lilly And Co	MOUNJARO (AUTOINJECTOR)	tirzepatide	SOLUTION;SUBCUTANEOUS	215866-005	May 13, 2022		RX	Yes	Yes	12,343,382
Eli Lilly And Co	ZEPBOUND	tirzepatide	SOLUTION;SUBCUTANEOUS	217806-010	Mar 28, 2024		RX	Yes	Yes	12,453,758
Eli Lilly And Co	ZEPBOUND (AUTOINJECTOR)	tirzepatide	SOLUTION;SUBCUTANEOUS	217806-003	Nov 8, 2023		RX	Yes	Yes	11,918,623
Eli Lilly And Co	MOUNJARO (AUTOINJECTOR)	tirzepatide	SOLUTION;SUBCUTANEOUS	215866-005	May 13, 2022		RX	Yes	Yes	12,453,755

EU/EMA Drug Approvals for TIRZEPATIDE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Eli Lilly Nederland B.V.	Mounjaro	tirzepatide	EMEA/H/C/005620Mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications- in addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4.4, 4.5 and 5.1.	Authorised	no	no	no	2022-09-15

International Patents for TIRZEPATIDE

Country	Patent Number	Title	Estimated Expiration
France	23C1006
South Korea	20250090374	GIP/GLP1 작용제 조성물 (GIP/GLP1 GIP/GLP1 AGONIST COMPOSITIONS)
Ukraine	118239	СПОЛУКА-КОАГОНІСТ GIP І GLP-1 (GIP AND GLP-1 CO-AGONIST COMPOUNDS)
Serbia	64288	KOMPOZICIJE AGONISTI GIP/GLP1 (GIP/GLP1 AGONIST COMPOSITIONS)

Supplementary Protection Certificates for TIRZEPATIDE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3242887	23C1006	France		PRODUCT NAME: TIRZEPATIDE; REGISTRATION NO/DATE: EU/1/22/1685 20220919
3242887	CA 2023 00005	Denmark		PRODUCT NAME: TIRZEPATID OG FARMACEUTISK ACCEPTABLE SALTE DERAF; REG. NO/DATE: EU/1/22/1685 20220919
3242887	SPC/GB23/006	United Kingdom		PRODUCT NAME: TIRZEPATIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF.; REGISTERED: UK EU/1/22/1685(FOR NI) 20220919; UK MORE ON HISTORY TAB 20220919
3242887	C202330010	Spain		PRODUCT NAME: TIRZEPATIDA Y SALES FARMACEUTICAMENTE ACEPTABLES DE LA MISMA; NATIONAL AUTHORISATION NUMBER: EU/1/22/1685; DATE OF AUTHORISATION: 20220915; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/22/1685; DATE OF FIRST AUTHORISATION IN EEA: 20220915

Market Dynamics and Financial Trajectory for Tirzepatide

Last updated: March 26, 2026

What Is Tirzepatide and Its Indications?

Tirzepatide is a dual GIP and GLP-1 receptor agonist developed by Eli Lilly. Approved by the FDA in May 2022 for type 2 diabetes, it is administered weekly. Its efficacy in reducing HbA1c and body weight exceeds that of existing GLP-1 receptor agonists.

Market Size and Growth Drivers

Diabetes and Obesity Markets

Tirzepatide targets two large, overlapping markets:

Market Segment	2022 Estimate (USD billion)	Compound Annual Growth Rate (CAGR)	Key Drivers
Type 2 Diabetes	58	7.5%	Rising prevalence, aging population
Obesity	27	9.0%	Increasing obesity rates, unmet needs

The global type 2 diabetes market generated $58 billion in 2022, expected to reach approximately $97 billion by 2030. The obesity segment is forecasted to grow at similar rates, driven by escalating obesity rates worldwide.

Competitive Landscape

Major competitors include:

• Semaglutide (Ozempatide, Wegovy): Improves glycemic control and weight loss.
• Dulaglutide (Trulicity): Long-active GLP-1 receptor agonist.
• Liraglutide (Victoza, Saxenda): Approved for both diabetes and obesity.

Tirzepatide's dual mechanism offers potential for superior efficacy, positioning it as a competitive advantage in these markets.

Orphan and Specialty Drug Status

Tirzepatide is not classified as an orphan drug. Its broad indications and high prevalence of target conditions qualify it as a high-volume specialty drug with blockbuster potential.

Regulatory and Reimbursement Landscape

FDA Approval and Labeling

• Approved in May 2022 for type 2 diabetes.
• Awaiting or pursuing additional indications, including obesity treatment.

Reimbursement Strategies

Price points for similar GLP-1 therapies range from $900 to $1,200 per month. Lilly set tirzepatide's list price at approximately $1,000 per month, aligning with competitors. Reimbursement success depends on payer evaluations of efficacy, safety, and cost-effectiveness.

Revenue Projections

Short-Term Outlook (2023-2025)

Eli Lilly projects sales of approximately $2 billion in 2023, climbing to $4-5 billion by 2025. Sales expansion will depend on:

• Uptake in existing markets
• Expansion into obesity indications
• Physician acceptance and patient adherence

Long-Term Outlook (2026 and Beyond)

Sales could reach $10 billion annually if tirzepatide secures additional approvals and adoption accelerates worldwide. Market penetration will be influenced by competition, pricing strategies, and regional regulation.

Year	Estimated Revenue Range (USD billion)	Assumptions
2023	2.0	Initial launch, high unmet need
2024	3.0-4.0	Market growth, indication expansion
2025	4.5-5.0	Global uptake, insurance coverage
2026+	8.0-10.0	Broader indications, increased penetration

Key Market Risks and Challenges

• Competitive pressure: Semaglutide’s proven efficacy may limit tirzepatide’s market share.
• Pricing and reimbursement: Payers may push for discounts or formulary restrictions.
• Regulatory risk: Additional indications could face approval delays.
• Manufacturing capacity: Meeting global demand requires scalable production.

Investment and R&D Outlook

Eli Lilly continues to invest in clinical trials for obesity, cardiovascular outcomes, and additional indications. R&D costs are substantial but are offset by expected market premiums and lifecycle revenue.

Conclusion

Tirzepatide's entry into the large and growing diabetes and obesity markets positions it for significant revenue generation. Competitive advantages stem from its dual mechanism, superior efficacy, and expanding indication profile. Long-term success hinges on regulatory approvals, market acceptance, and strategic pricing.

---

Key Takeaways

• Tirzepatide targets large markets with high growth potential: diabetes (~$58 billion) and obesity (~$27 billion).
• Sales are projected to reach $4-5 billion by 2025, with long-term potential exceeding $10 billion annually.
• Competition from established GLP-1 therapies is intense, emphasizing the importance of efficacy and reimbursement.
• Regulatory and manufacturing challenges could impact market penetration and revenues.
• Strategic indication expansion and regional adoption will influence long-term financial outcomes.

---

Frequently Asked Questions

1. How does tirzepatide differ from existing GLP-1 receptor agonists?
It combines GIP and GLP-1 receptor agonism, providing greater HbA1c reduction and weight loss benefits compared to GLP-1 therapies alone.

2. What factors could limit tirzepatide's market growth?
Intense competition, payer restrictions, regulatory delays for new indications, and manufacturing capacity limitations.

3. Are there additional indications under development?
Yes, Eli Lilly is exploring obesity and cardiovascular outcome indications, which could significantly expand the market.

4. What is the pricing strategy for tirzepatide?
The initial list price aligns with existing GLP-1 therapies at around $1,000 per month, emphasizing value based on efficacy.

5. When could tirzepatide reach peak sales?
If indicated for multiple conditions and adopted globally, peak sales could exceed $10 billion annually by 2030.

---

References

[1] GlobalData. (2022). Market analysis of type 2 diabetes therapies.
[2] Eli Lilly. (2022). Press release on FDA approval of tirzepatide.
[3] Grand View Research. (2022). Obesity and diabetes drug markets.
[4] IQVIA. (2023). Pharmaceutical market forecast.
[5] FDA. (2022). Tirzepatide approval announcement.